Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06123026 · ClinicalTrials.gov registry record · Phase 4
Pharmacological Inhibition of Lactation After 16 to 20 Week Abortion
A Phase 4 study of Lactation Suppressed and Second Trimester Abortion, sponsored by Northwestern University.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 200
- Enrollment target
- 1
- Study location
NCT06123026: Recruiting Phase 4 study of Lactation Suppressed and Second Trimester Abortion, sponsored by Northwestern University.
NCT06123026 is a Phase 4 study of Lactation Suppressed and Second Trimester Abortion that is actively recruiting participants, run by Northwestern University. The registered enrollment target is 200 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (61% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06123026, a Phase 4 study of Lactation Suppressed and Second Trimester Abortion, is actively recruiting participants, sponsored by Northwestern University.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 200 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this clinical trial is to compare breast symptoms (lactation, engorgement, etc) of individuals who undergo a procedure for second trimester of pregnancy loss between 16 weeks and 20 weeks gestational age. The participants will be randomly placed in two groups, one with a placebo tablet and one with medication called "cabergoline" which are taken immediately after their procedure. Researchers will compare groups to see if there are any significant differences in breast symptoms.
Primary Outcome
Using the bristol breast inventory to assess breast symptoms (engorgement, lactation, etc).
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Cabergoline
Study Locations (1)
Illinois
- Northwestern Medical Center - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2023-12-18 |
| Est. Completion | 2024-06-30 |
| Phase | Phase 4 |
What NCT06123026 shows while recruiting
NCT06123026 is an interventional study that assigns participants to a tested intervention. The registered 200 participants enrollment target is mid-sized for trials with a published cap, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (61% lower).
The record links to 2 conditions, with Lactation Suppressed appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06123026 reports a single indexed study location in Illinois.
Frequently Asked Questions
What is clinical trial NCT06123026 about?
NCT06123026 is a clinical study titled "Pharmacological Inhibition of Lactation After 16 to 20 Week Abortion". The goal of this clinical trial is to compare breast symptoms (lactation, engorgement, etc) of individuals who undergo a procedure for second trimester of pregnancy loss between 16 weeks and 20 weeks gestational age. The participants will be randomly placed in two groups, one with a placebo tablet a...
What is the current status of trial NCT06123026?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 200 participants. The study started on 2023-12-18. Estimated completion is 2024-06-30.
What conditions does trial NCT06123026 study?
This clinical trial studies the following conditions: Lactation Suppressed, Second Trimester Abortion.
What interventions are being tested in trial NCT06123026?
The interventions under investigation include: Placebo (DRUG), Cabergoline (DRUG).
Who is sponsoring clinical trial NCT06123026?
This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06123026 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lactation Suppressed
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06123026's enrollment target sits among peer trials
200 407th of 2000 higher than 1,557 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00107289 · 200 participants · Phase 2
Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma
- NCT00109174 · 200 participants · NA
MRS Measurement of Glutamate and GABA Metabolism in Brain
- NCT00177268 · 200 participants
Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research
- NCT00493688 · 200 participants
A Study to Determine Whether Perioperative Energy Dynamics Correlates With Postoperative Outcomes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI